Literature DB >> 22777943

Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis.

Y Yin1, X Wu, G Shan, X Zhang.   

Abstract

The autoantibodies against C1q (anti-C1q) have been reported in patients with systemic lupus erythematosus (SLE). In the past decade, though there were increasing studies suggesting it is relatively specific in lupus nephritis (LN), its overall diagnostic value in LN has not been evaluated. The meta-analysis was conducted to quantitatively evaluate the diagnostic accuracy of autoantibodies against C1q in patients with LN, and to provide more precise evidence of a correlation between anti-C1q antibodies and activity of LN. We searched Medline, Embase and Cochrane databases and contacted authors if necessary. A total of 25 studies including 2,502 patients with SLE and 1,317 with LN met our inclusion criteria for this meta-analysis. Among all 25 studies, 22 studies were available for comparison between SLE with and without LN, and 9 studies compared anti-C1q between patients with active and inactive LN. Summary receiver operating characteristic (SROC) curve was used to summarize comprehensive test performance. The QUADAS tool was used to assess the quality of the studies. For the diagnosis of LN, the pooled sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of anti-C1q were 0.58 (0.56-0.61, 95% confidence interval [95% CI]), 0.75 (0.72-0.77, 95% CI), 2.60 (2.06-3.28, 95% CI), 0.51 (0.41-0.63, 95% CI), and 6.08 (3.91-9.47, 95% CI) respectively. The area under the SROC curve (AUC) was 0.7941. For comparison between active and inactive LN, the weighted sensitivity, specificity, PLR, NLR and DOR were 0.74 (0.68-0.79, 95% CI), 0.77 (0.71-0.82, 95% CI), 2.91 (1.83-4.65, 95% CI), 0.33 (0.19-0.56, 95% CI), and 10.56 (4.56-24.46, 95% CI) respectively. The AUC was 0.8378. In conclusion, this meta-analysis indicates that anti-C1q antibodies have relatively fair sensitivity and specificity in the diagnosis of LN, suggesting that the presence of anti-C1q antibodies may be a valuable adjunct for predicting LN and assessing renal activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22777943     DOI: 10.1177/0961203312451202

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  22 in total

Review 1.  Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise.

Authors:  Daniel J Birmingham; Michael Merchant; Sushrut S Waikar; Haikady Nagaraja; Jon B Klein; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

Review 2.  Complement in Lupus Nephritis: New Perspectives.

Authors:  Lihua Bao; Patrick N Cunningham; Richard J Quigg
Journal:  Kidney Dis (Basel)       Date:  2015-06-30

Review 3.  Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.

Authors:  Abhigyan Satyam; Ryo Hisada; Rhea Bhargava; Maria G Tsokos; George C Tsokos
Journal:  Transl Res       Date:  2022-03-14       Impact factor: 10.171

4.  Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus.

Authors:  Lukas Bossaller; Vijay A K Rathinam; Ramon Bonegio; Ping-I Chiang; Patricia Busto; Adam R Wespiser; Daniel R Caffrey; Quan-Zhen Li; Chandra Mohan; Katherine A Fitzgerald; Eicke Latz; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

5.  Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.

Authors:  Daniel J Birmingham; Joshua E Bitter; Ezinne G Ndukwe; Sarah Dials; Terese R Gullo; Sara Conroy; Haikady N Nagaraja; Brad H Rovin; Lee A Hebert
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

6.  Complement Deficiencies Result in Surrogate Pathways of Complement Activation in Novel Polygenic Lupus-like Models of Kidney Injury.

Authors:  Sladjana Skopelja-Gardner; Lucrezia Colonna; Payton Hermanson; Xizhang Sun; Lena Tanaka; Joyce Tai; Yenly Nguyen; Jessica M Snyder; Charles E Alpers; Kelly L Hudkins; David J Salant; YuFeng Peng; Keith B Elkon
Journal:  J Immunol       Date:  2020-04-01       Impact factor: 5.422

Review 7.  Complement System Part II: Role in Immunity.

Authors:  Nicolas S Merle; Remi Noe; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-05-26       Impact factor: 7.561

Review 8.  Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases.

Authors:  Brent J Ryan; Ahuva Nissim; Paul G Winyard
Journal:  Redox Biol       Date:  2014-05-28       Impact factor: 11.799

9.  Anti-C1q autoantibodies, novel tests, and clinical consequences.

Authors:  Michael Mahler; Rosanne A van Schaarenburg; Leendert A Trouw
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

10.  Antibodies against C1q Are a Valuable Serological Marker for Identification of Systemic Lupus Erythematosus Patients with Active Lupus Nephritis.

Authors:  Shuhong Chi; Yunxia Yu; Juan Shi; Yurong Zhang; Jijuan Yang; Lijuan Yang; Xiaoming Liu
Journal:  Dis Markers       Date:  2015-10-13       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.